Getting your player ready...
Shares of Boulder-based drug developer Array BioPharma Inc. jumped Monday after the company said its drug candidate, ARRY-797, reduced pain in a midstage study and it will next compare the treatment with Pfizer’s Celebrex.
Shares surged 96 cents, or 17.1 percent, to close at $6.56 Monday. The stock has traded between $5.03 and $14.59 over the past 52 weeks. ARRY-797 reduced patients’ pain after dental surgery in the Phase II clinical trial.
